Protalix Biotherapeutics, Inc. (PLX) Announces Data On Oral Antitnf To Be Presented At Digestive Disease Week 2014 Meeting
4/23/2014 9:15:31 AM
CARMIEL, Israel, April 23, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that preclinical data on oral antiTNF (PRX-106) was accepted for presentation at the Digestive Disease Week (DDW) Annual Meeting being held May 3-6 in Chicago, Illinois.
Help employers find you! Check out all the jobs and post your resume.
comments powered by